RT MartyParty (@martypartymusic)New @solana DAT: Sharps Technology, Inc. Announces Over $400 Million Private Placement Seeking to Establish the Largest Solana Digital Asset Treasury StrategyNew York – August 25, 2025 – Sharps Technology, Inc. (the “Company” or “Sharps Technology”) (NASDAQ: “STSS” and “STSSW”) today announced the pricing of a private placement offering to support its plans to adopt a digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of th ...

Core Points - ETHZilla Corporation has authorized a stock repurchase program of up to $250 million of its outstanding shares, effective immediately [1][6] - The company holds a total of 102,237 Ether (ETH) at an average acquisition price of $3,948.72, valued at approximately $489 million [1][7] - In addition to ETH, ETHZilla has approximately $215 million in USD cash equivalents [1][7] Company Strategy - The company is focused on deploying capital to accelerate its Ethereum treasury strategy and aims to maximize shareholder value through the stock repurchase program [2] - ETHZilla's treasury strategy includes a partnership with Electric Capital to pursue differentiated yield generation opportunities that aim to outperform traditional ETH staking [12] - The company is evolving from a biotechnology focus to include software-enabled gaming and entertainment, while continuing to develop its ETH treasury strategy [13] Financial Metrics - As of August 24, 2025, ETHZilla's total ETH and ETH equivalents held is 102,237, valued at approximately $489 million [7] - The company has issued 3.3 million shares through at-the-market offerings, raising net proceeds of approximately $20.9 million [4] - The average purchase price of ETH has increased from $3,807 to $3,949 over the past few weeks [4]

Core Viewpoint - Sharps Technology, Inc. is implementing a digital asset treasury strategy focused on accumulating SOL, the native digital asset of the Solana blockchain, to leverage its high transaction throughput and yield generation capabilities [1][18]. Company Overview - Sharps Technology is a medical device and pharmaceutical packaging company that offers patented smart-safety syringe products, focusing on ultra-low waste capabilities and specialized copolymer technology for pre-fillable syringes [17]. Digital Asset Strategy - The company has announced a private placement offering of over $400 million to support its digital asset treasury strategy, with a primary focus on acquiring SOL [6][9]. - The offering includes common stock and stapled warrants at a purchase price of $6.50 per unit, with warrants exercisable for three years at an exercise price of $9.75 [6][8]. - The net proceeds from the offering will be used to fund the acquisition of SOL, establish treasury operations, and for general corporate purposes [9]. Solana Blockchain Insights - Solana is recognized as the fastest and most used public blockchain, processing more transactions and generating more on-chain fee revenue than all other blockchains combined [1][5]. - The blockchain offers approximately 7% staking yields, the highest among the top five major blockchains, and has generated $1.3 billion in revenue for apps year-to-date [4][7]. - Solana supports over 7,500 new developers in 2024, making it the fastest-growing blockchain ecosystem by developer count [7]. Leadership and Advisory Team - Alice Zhang has been appointed as the Chief Investment Officer, bringing experience from her previous role at Jambo, and will lead the digital asset treasury strategy [2][10]. - James Zhang, co-founder of Jambo, will serve as a strategic advisor, collaborating with top-tier asset managers to grow the digital asset treasury [3][11]. Institutional Support - The global adoption of Solana's ecosystem is accelerating, with increasing institutional support for its vision of a unified market for tradeable assets [2]. - The company has signed a non-binding letter of intent with the Solana Foundation to purchase $50 million of SOL at a 15% discount, contingent on certain conditions [9].

Core Viewpoint - Cosmos Health Inc. has initiated the purchase of Ethereum (ETH) as part of its digital asset treasury reserve strategy, marking a significant step towards integrating cryptocurrency into its financial strategy [1][2]. Group 1: Company Strategy - The company has completed an initial purchase of $1 million in ETH, utilizing a financing facility of up to $300 million with a U.S.-based institutional investor [1]. - CEO Greg Siokas expressed enthusiasm about building an ETH treasury, indicating a shift from holding only cash to incorporating assets with strong appreciation potential [2]. - The strategic move is supported by the growing adoption of ETH by institutional investors, its inclusion in ETFs, and the proposed expansion of cryptocurrency access in retirement plans [2]. Group 2: Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [3]. - The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands and operates under European Good Manufacturing Practices (GMP) [3]. - Cosmos Health is expanding its global distribution platform and has established R&D partnerships targeting major health disorders, enhanced by AI drug repurposing technologies [3].

Core Viewpoint - 180 Life Sciences Corp. (d/b/a ETHZilla) is focusing on increasing its Ethereum (ETH) holdings through a recent $156 million convertible notes offering, which is part of its broader ETH treasury strategy [1][2][6] Group 1: Financing and Strategy - The company has closed a $425 million private placement and subsequently sold approximately $156 million in senior secured convertible notes due 2028 [1][2] - Proceeds from the convertible notes will primarily be used to purchase more ETH and support the company's ETH treasury strategy [2][3] - The convertible notes will not accrue interest for the first six months and will have a 4% annual interest rate thereafter, maturing three years from the issuance date [2] Group 2: Company Operations and Future Plans - The company aims to rebrand as ETHZilla Corporation and establish itself as a leader in on-chain treasury management among public companies [6] - A significant portion of the company's operations will focus on becoming an ETH accumulation vehicle, designed to provide community access to the Ethereum network [7] - The company plans to implement a differentiated yield generation program in partnership with Electric Capital, aiming to outperform traditional ETH staking [7] Group 3: Legal and Advisory Support - Clear Street LLC acted as the financial advisor and exclusive placement agent for the convertible notes offering, while The Loev Law Firm, PC and Reed Smith LLP provided legal advice to the company [4]

Core Insights - Artelo Biosciences, Inc. has entered into a securities purchase agreement for a PIPE, raising approximately $9.475 million through the sale of 906,687 shares of common stock and associated warrants [1][5] - The company plans to utilize the proceeds to launch a Solana-centric digital asset treasury strategy, marking it as the first publicly traded pharmaceutical company to adopt Solana's native cryptocurrency, SOL, as a reserve asset [2][13] - Bartosz Lipiński, a key figure in the Solana ecosystem, will serve as a technical partner for Artelo's treasury initiative, emphasizing the strategic importance of this move for the company's growth [3][4] Financial Strategy - The funds raised will support Artelo's ongoing business and its innovative treasury initiative, which aims to diversify its balance sheet and enhance liquidity management [2][5] - The treasury strategy is designed to preserve working capital for the continued development of Artelo's proprietary therapeutics while providing exposure to a next-generation monetary network [13] Market Positioning - Artelo's adoption of SOL positions the company at the intersection of biotechnology and decentralized finance, showcasing its commitment to forward-thinking financial management [2][4] - The integration of SOL into Artelo's treasury strategy is expected to enhance shareholder value and demonstrate leadership in the evolving capital landscape of the biotech sector [5][13] Solana Overview - Solana, launched in 2020, is recognized for its high-performance blockchain capabilities, processing over 35.99 million daily transactions and boasting a Total Value Locked (TVL) of $89.417 billion, surpassing Ethereum [11][10] - The network's scalability and decentralized infrastructure are highlighted as key advantages, making it a cornerstone of the future financial ecosystem [4][10]

Core Insights - Profusa, Inc. has made an initial investment of $1 million in Bitcoin as part of its treasury strategy to hedge against macroeconomic uncertainties [1] - The company has partnered with BlockFills to implement its Bitcoin treasury management strategy [1] - Profusa's CEO emphasized the importance of this investment in maximizing their Bitcoin holdings while maintaining capital for their AI-driven digital health platform [2] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors for continuous monitoring of biochemistry [3] - The company aims to provide personalized biochemical data through its long-lasting, injectable biosensors and intelligent data platform [3] - Profusa is led by a team of experienced management and a world-class board of directors [3]

Upexi (UPXI) Conference Call Summary Company Overview - Upexi Incorporated is identified as a leading Solana treasury company and a consumer products brand owner [3][4] - The company currently generates approximately $15 to $20 million in annual recurring revenue and is breakeven [4] Financial Strategy - Upexi has raised $100 million from 15 prestigious crypto venture capital funds to support its Solana treasury strategy [4] - The company aims to acquire and hold as much Solana as possible, leveraging its management team's expertise [4][5] Digital Asset Treasury Model - Upexi's strategy is influenced by MicroStrategy's model of holding digital assets, which has proven successful since August 2020 [6][7] - Digital asset treasury companies can provide shareholder benefits that may surpass direct cryptocurrency investments, including: - Acting as a proxy for the underlying digital asset [7] - Trading with a beta to the cryptocurrency [7] - Engaging in multiple value accrual mechanisms [8] Solana as a Strategic Asset - Solana is positioned as the leading smart contract blockchain with superior technology and a vibrant ecosystem [12][35] - Upexi believes that Solana has significant upside potential compared to Bitcoin, with a market cap only 4% that of Bitcoin's [23][34] Value Accrual Mechanisms - Upexi employs several strategies to enhance shareholder value: - Staking Solana to earn an approximate 8% return [19][20] - Purchasing locked Solana at a discount for built-in gains [21][22] - Intelligent capital issuance to raise funds in an accretive manner [15][25] Market Position and Future Outlook - Upexi is the largest Solana treasury company by the number of Solana held, with nearly 700,000 Solana valued at over $120 million [27][28] - The company anticipates a potential crypto bull market driven by clearer regulations in the U.S. [31][32] - Upexi's management team is noted for its connectivity in both the crypto and traditional finance sectors, enhancing its market visibility [36] Risks and Challenges - The company acknowledges the volatility of cryptocurrency prices and the importance of the underlying token's performance for success [39] - Upexi has committed to a buy-and-hold strategy exclusively for Solana, indicating a focused investment approach [38] Conclusion - Upexi presents itself as a unique investment opportunity in the digital asset space, leveraging its treasury strategy and management expertise to capitalize on the growth of Solana and the broader cryptocurrency market [37][36]

Core Insights - Eyenovia, Inc. is advancing its digital asset capital strategy by building a strategic treasury of HYPE, the native token of the Hyperliquid protocol [1][7] - Avenue Capital Group has become the largest common stockholder and has amended Eyenovia's senior secured debt to support the HYPE treasury, extending the maturity date to July 1, 2028, and reducing the interest rate from 12% to 8% [2] - Max Fiege has been appointed as Strategic Advisor to enhance the HYPE Treasury strategy, focusing on stakeholder education and ecosystem advocacy [4] Financial Developments - The amendment to the debt includes interest-only payments for the first 18 months, followed by equal principal and interest payments for the next 18 months [2] - The reduced interest rate and extended maturity are expected to provide financial flexibility as the company builds its HYPE treasury [2] Strategic Appointments - Max Fiege, with a background in blockchain and digital assets, will assist in the treasury architecture and risk oversight for Eyenovia [4][5] - His expertise is anticipated to enhance the company's position in the digital finance landscape [5] HYPE Token Overview - HYPE is the native token of the Hyperliquid layer one blockchain, allowing for non-custodial trading and offering utility such as trading fee discounts [6] - As of June 2025, HYPE ranks as the 12th-largest cryptocurrency by market capitalization [6] Company Overview - Eyenovia is a pioneering digital ophthalmic technology company, focusing on both innovative eye treatment solutions and building a treasury of HYPE [7] - The company is also developing the Optejet User Filled Device, targeting multiple billion-dollar markets in ophthalmic treatments [8]

Core Viewpoint - DeFi Development Corp. has made a strategic investment in Solana, acquiring 20,473 SOL for approximately $2.97 million, bringing its total holdings to 420,690 SOL valued at around $61.9 million, including staking rewards [1][2][7] Group 1: Company Strategy - The company has adopted a treasury policy focusing on Solana (SOL) as its principal holding, aiming to provide investors with access to the Solana ecosystem [3] - The recently purchased SOL will be held long-term and staked with various validators, including the company's own Solana validators, to generate native yield [2][3] Group 2: Financial Metrics - Total SOL held by the company is 420,690, valued at approximately $61.9 million [7] - The total shares outstanding are 2,011,887, resulting in a SOL per share (SPS) of 0.209 and an SPS value of $30.78 [7]